证券代码：000534 证券简称：万泽股份 公告编号:2025-086 万泽实业股份有限公司 关于为下属子公司提供担保的进展公告 1 不超过 56 亿元，担保额度的授权期限自公司 2024 年度股东大会审议通过 之日至公司 2025 年度股东大会召开之日止，担保额度在授权期限内可循环 使用，担保额度可根据实际情况在公司和下属子公司间进行调剂，其中万 泽中南研究院的额度为 3 亿元、上海万泽的额度为 8 亿元，具体内容详见 公司相关公告（公告编号：2025-024、025、057）。因此本次公司为万泽中 南研究院、上海万泽所获授信额度提供的担保未超过上述额度，无需提交 公司董事会、股东大会审议批准。 上述担保提供前，本公司对万泽中南研究院的担保余额为 6,000 万元、 对上海万泽的担保余额为 38,378.41 万元；上述担保提供后，本公司对万泽 中南研究院的担保余额为 7,000 万元、对上海万泽的担保余额为 43,378.41 万元。 二、被担保人情况介绍 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 万泽实业股份有限公司（以下简称"公 ...

Summary of Gas Turbine Industry Conference Call Industry Overview - The global gas turbine market is projected to reach approximately $21.5 billion in 2024 and is expected to grow to $34.4 billion by 2033, with a compound annual growth rate (CAGR) of about 5% [1][8] - The increasing demand for electricity in data centers, driven by the proliferation of AI applications, is expected to further boost market growth [1][3] Core Insights and Arguments - Data centers are significant energy consumers, with IT equipment accounting for about 50% of their energy usage, and servers making up approximately 80% of the IT equipment [1][5] - Gas power generation is cleaner compared to coal and offers cost advantages under carbon neutrality goals; it also provides stable peak-shaving capabilities, making it suitable for distributed energy systems [1][13] - The demand for clean, efficient, and responsive gas turbines is increasing due to strict requirements for backup power systems in high-grade data centers [1][7] - The gas turbine market is benefiting from significant order growth from leading overseas OEMs such as Mitsubishi Power, GE Energy, and Siemens, while domestic companies like Yingli Co., Hangya Technology, and Hangyu Technology are also gaining from overseas demand [1][15][22] Development Trends - Short-term growth in overseas market demand is expected to drive performance increases for related companies [3] - Long-term prospects for the domestic gas turbine market are improving as domestic companies achieve significant advancements, such as the launch of a 300 MW F-class gas turbine and breakthroughs in heavy gas turbine technology [3][18] - The introduction of AI applications is projected to significantly increase electricity consumption in data centers, further driving gas turbine demand [3][9] Market Dynamics - The gas turbine market is characterized by a stable compound growth rate of about 20% over the past decade, with emerging markets like Asia-Pacific and the Middle East showing particularly strong performance [9] - The introduction of AI-optimized servers is expected to add $10 to $20 billion annually to the market size from 2024 to 2027, potentially reaching a cumulative market size of $60 billion by 2027 [9] Key Players and Competitive Landscape - Major players in the gas turbine market include Siemens and Mitsubishi Power, which have significant technological and market advantages, covering a full spectrum of products from large to small gas turbines [16] - Domestic companies are making strides in technology and market penetration to compete with these global leaders [16][18] Cost Structure and Component Value - In terms of component value distribution, the turbine blades account for approximately 36% of the total, while the power turbine holds the highest share at 31% [20] - The cost structure of gas turbines is composed of about 50% raw materials, 25% labor, and 25% manufacturing costs, with high-temperature alloys making up 35% of raw material costs [21] Domestic Industry Progress - Domestic companies have made significant progress during the 14th Five-Year Plan period, with advancements in the development of heavy gas turbines and a focus on achieving domestic substitution [18][19] - Companies like China Heavy Gas Turbine and China Aviation Power are focusing on large and lightweight gas turbine designs, respectively, creating a differentiated competitive landscape [19] Conclusion - The gas turbine industry is poised for growth driven by technological advancements, increasing energy demands from data centers, and a shift towards cleaner energy sources. The competitive landscape is evolving with both international and domestic players making significant strides in technology and market presence.

万泽实业股份有限公司 关于参加 2025 年广东辖区投资者网上集体接待日活动的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 | | --- | | 虚假记载、误导性陈述或重大遗漏。 | 为进一步加强与投资者的互动交流，万泽实业股份有限公司（以下简 称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提 质 价值领航——2025 年广东辖区投资者集体接待日暨辖区上市公司中报 业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网 站（http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五）15:30-17:00。 证券代码：000534 证券简称：万泽股份 公告编号:2025-085 届时公司高管将在线就 2025 年半年度业绩、公司治理、发展战略、经 营状况、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与！ 特此公告。 万泽实业股份有限公司 董 事 会 2025 年 9 月 16 日 ...

证券代码：000534 证券简称：万泽股份 公告编号:2025-084 2025 年 6 月 30 日，公司 2024 年度股东大会审议通过《关于拟向相关 金融机构申请综合授信额度的议案》《关于确定担保额度的议案》等议案， 同意公司（含公司合并报表范围内的下属子公司）向银行等金融机构申请 综合授信业务和与具有相应资质的金融公司合作进行融资业务，并由本公 司或子公司为上述融资业务提供连带责任担保，担保对象为公司及合并报 表范围内的下属子公司，担保方式包括但不限于保证担保、信用担保、资 产抵押、质押等以及因业务需要向相关方视情况提供的反担保，担保额度 不超过 56 亿元，担保额度的授权期限自公司 2024 年度股东大会审议通过 之日至公司 2025 年度股东大会召开之日止，担保额度在授权期限内可循环 使用，担保额度可根据实际情况在公司和下属子公司间进行调剂，其中万 泽航空的额度为 5 亿元，具体内容详见公司相关公告（公告编号：2025-024、 1 025、057）。因此本次公司为万泽航空所获授信额度提供的担保未超过上述 额度，无需提交公司董事会、股东大会审议批准。 上述担保提供前，本公司对万泽航空的担保余额为 ...

Group 1 - The company announced the convening of its third extraordinary general meeting of shareholders for 2025 on September 8, 2025 [2] - The meeting approved the proposal regarding the repurchase and cancellation of a portion of the company's restricted stock [2]

证券代码：000534 证券简称：万泽股份 公告编号:2025-083 万泽实业股份有限公司 公司本次回购注销部分限制性股票将导致注册资本减少，根据《中华 人民共和国公司法》（以下简称"《公司法》"）等相关法律、法规的规定， 1 公司特此通知债权人。 二、通知债权人 公司本次回购注销部分限制性股票将导致公司股份总数减少 564,800 股，公司注册资本减少 564,800 元，在公司股份总数不发生其他变动的前提 下，公司股份总数将由 509,835,816 股减少至 509,271,016 股。根据《公司 法》等相关法律、法规的规定，债权人自本公告之日起 45 日内，有权凭有 效债权文件及相关凭证要求公司清偿债务或者提供相应担保。债权人未在 规定期限内行使上述权利的，不影响其债权的有效性，相关债务将由公司 根据原债权文件的约定继续履行。 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 债权人可采用现场申报或信函的方式申报，债权申报所需材料：公司 债权人可持证明债权债务关系存在的合同、协议及其他凭证的原 ...

证券代码：000534 证券简称：万泽股份 公告编号: 2025-082 万泽实业股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开时间 现场会议召开时间：2025年9月8日下午14时30分； 网络投票时间： 通过深圳证券交易所交易系统投票时间为：2025年9月8日9:15-9:25， 9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年9月8 日9:15-15:00。 2、会议召开地点 深圳市福田区福强路2016号云顶翠峰裙楼一楼会议室。 1 公司董事长黄振光先生。 6、会议的出席情况 参加现场会议和网络投票的股东（或股东代理人）合计185人，代表有 表决权的股份数为191,808,167股，占公司有表决权股份总数482,639,659股的 39.7415%（截至股权登记日公司总股本为509,835,816股，其 ...

广东信达律师事务所 股东大会法律意见书 中国 深圳 福田区益田路6001号太平金融大厦11、12楼 邮政编码：518038 11-12/F, Taiping Finance Tower, Yitian Road 6001, Futian District，Shenzhen, P. R. China 电话(Tel)：(0755)88265288 传真(Fax) ：(0755) 88265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：www. sundiallawfirm.com 广东信达律师事务所 关于万泽实业股份有限公司 2025 年第三次临时股东大会的法律意见书 信达会字[2025]第 250 号 致：万泽实业股份有限公司 广东信达律师事务所（下称"信达"）接受万泽实业股份有限公司（下称"贵 公司"或"公司"）的委托，指派信达律师出席贵公司 2025 年第三次临时股东大 会（下称"本次股东大会"），对贵公司本次股东大会的合法性进行见证，并出具 本《广东信达律师事务所关于万泽实业股份有限公司 2025 年第三次临时股东大 会的法律意见书》（下称"《股 ...

Core Viewpoint - The recent suspension of procurement qualifications for 28 commonly used clinical drugs in Shanghai due to non-compliance with price adjustment requirements reflects a broader national initiative aimed at regulating drug prices and ensuring fairness across provinces [2][3][9]. Group 1: Price Adjustment and Impact - The suspended drugs include essential items such as Banlangen Granules and Chuanxinlian Tablets, with notable companies like Taiji Group and Tianjin Tongrentang affected [2][3]. - The price adjustment initiative is part of a national strategy to eliminate price discrepancies between provinces, ensuring local prices do not exceed national monitoring levels [2][8]. - Previous price adjustments in Inner Mongolia for Banlangen Granules have set a precedent, indicating a coordinated effort across regions to enforce price compliance [7][9]. Group 2: Market Dynamics and Responses - The price adjustment has led to a complex dynamic where companies are reluctant to forfeit profit margins while also needing to comply with regulatory demands [7][9]. - Despite the procurement suspensions, there are no immediate concerns about clinical supply shortages, as there are numerous production batches available for the affected drugs [8]. - The price governance has expanded to include unselected drugs in national procurement, indicating a shift in regulatory focus [8][9]. Group 3: Regulatory Developments - The National Medical Insurance Administration has implemented various measures to monitor and control drug prices, including the use of big data and online price comparisons [10][9]. - The ongoing centralized procurement efforts have led to significant price reductions and increased competition among pharmaceutical companies [10][9]. - The regulatory landscape is evolving towards a more coordinated approach, although challenges remain in balancing regional cost variations and supply impacts [10].

Core Viewpoint - The company announced the completion of the second unlock period for its 2023 stock incentive plan, allowing for the release of restricted stocks [1] Summary by Relevant Sections - **Stock Incentive Plan** - The company has a stock incentive plan for 2023, which includes the first grant of restricted stocks [1] - **Unlock Conditions** - The conditions for the second unlock period have been met, allowing for the release of restricted stocks [1] - **Number of Participants and Shares** - A total of 168 participants are eligible for the release, with 1,665,000 shares being unlocked, representing 0.3266% of the company's total share capital [1] - **Listing Date** - The unlocked restricted stocks will be available for trading starting from September 5, 2025 [1]